Australian researchers spearhead paradigm shift in melanoma treatment

Australian researchers spearhead paradigm shift in melanoma treatment

20 September 2021

In what has been described as a paradigm shift in the treatment of melanoma, drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients to stop disease spread and save lives.

Promising results from an international multi-centre clinical trial, which included researchers and patients from Melanoma Institute Australia (MIA), were presented this weekend at the prestigious European Society for Medical Oncology (ESMO) Congress.

Results showed giving high-risk Stage II melanoma patients the same immunotherapy drugs approved for use in advanced melanoma patients, reduced the risk of their disease returning or death by 35%.

Study author Professor Georgina Long AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, said the findings would result in a paradigm shift in treatment of early stage patients.

‘We are using drug therapy already proven to be life-saving for advanced melanoma patients, to stop the disease in its tracks in earlier stage patients,’ Professor Long said. ‘These exciting clinical trial results are strong evidence to support approval for this immunotherapy to become standard treatment for high-risk  Stage II patients in Australia.’

The clinical trial demonstrated that giving pembrolizumab (Keytruda™) after surgery to patients with Stage IIB or IIC melanoma (deemed at high risk of spread due to tumour thickness or ulceration) reduced the risk of the disease returning or death by 35% compared to placebo. At 12 months, only 9.5% of patients on pembrolizumab had their melanoma progress, compared to 16.9% in the placebo group.

In the last decade, the approval of immunotherapy for Stage III and IV melanoma patients has dramatically increased survival rates, with more than 50% of these patients now essentially cured.

However, there are no immunotherapy drugs currently approved for use in Stage II melanoma patients. They instead have to adopt a ‘watch-and-wait’ approach after surgery to see if their cancer will return or spread. Patients with thick Stage II melanoma also often undergo an invasive Sentinel Node Biopsy to check for disease spread, with drug therapy only available once their disease has spread to their lymph nodes (Stage III).

Fellow study author Professor Richard Scolyer AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, says the clinical trial results stand to transform how earlier stage disease is managed.

‘By giving this immunotherapy treatment at an earlier stage, we are proactively preventing melanoma spread,’ Professor Scolyer said.

Australia has the highest melanoma rates in the world with one person diagnosed with the disease every 30 minutes. An estimated 1300 Australians are expected to die from melanoma this year.

Following these clinical trial results, it is hoped pembrolizumab will soon come before the Pharmaceutical Benefits Advisory Committee (PBAC) for approval for use in these patients in Australia.

‘This proactive approach to preventing disease spread represents a significant step forward in our mission of reaching zero deaths from melanoma,’ Professor Scolyer added.

___________________________________________________________________________

The full data set was presented at ESMO on Saturday 18 September 2021 at 11:05pm (AEST) by Associate Professor Jason Luke in a presentation entitled: “Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial”.
Melanoma Institute Australia is affiliated with The University of Sydney and Professor Scolyer and Professor Long lead the Translational Research Group at the Charles Perkins Centre.
 

Media contact:

Jennifer Durante |media@melanoma.org.au | 0412 798 990

Congratulations to Kaye Oakley
29 Mar 2018

Congratulations to Kaye Oakley

A round of applause for a well deserved win.

Farewell from Carole Renouf, CEO of Melanoma Institute Australia
26 Mar 2018

Farewell from Carole Renouf, CEO of Melanoma Institute Australia

A message from our CEO, Carole Renouf

Marching in the twilight
26 Mar 2018

Marching in the twilight

Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma. 

Researchers uncover treatment sequence for advanced melanoma patients
23 Mar 2018

Researchers uncover treatment sequence for advanced melanoma patients

Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.

An unsung hero of melanoma care for nearly 30 years
22 Mar 2018

An unsung hero of melanoma care for nearly 30 years

Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.

Sharing our research on melanoma surgery
21 Mar 2018

Sharing our research on melanoma surgery

MIA is sharing it's research with the global surgical oncology community this week at the Society of Surgical Oncology Annual Cancer Symposium.

14 Melanoma Marches down, 7 to go!
19 Mar 2018

14 Melanoma Marches down, 7 to go!

It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.

Melanoma March keeps marching
14 Mar 2018

Melanoma March keeps marching

Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.

Melanoma March kicks off for 2018
08 Mar 2018

Melanoma March kicks off for 2018

Melanoma Institute Australia's annual fundraising initiative is all systems go!

Calls for urgent crackdown on illegal backyard solariums
07 Mar 2018

Calls for urgent crackdown on illegal backyard solariums

The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma
28 Feb 2018

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate. 

Excision margins for melanoma redefined
21 Feb 2018

Excision margins for melanoma redefined

Updated guidelines defining appropriate excision margins have been published thanks to research from MIA. 

A Pawsome Story of Hope
21 Feb 2018

A Pawsome Story of Hope

Joanne and her trusty companion Frankie spend their days spreading a message of hope in hospitals, nursing homes, even prisons. It is a long way from her darkest hour facing palliative care. This is her story of hope.

A new generation of melanoma researchers
15 Feb 2018

A new generation of melanoma researchers

Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.

Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
13 Feb 2018

Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide

The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.

Prestigious award in pathology for Professor Scolyer
09 Feb 2018

Prestigious award in pathology for Professor Scolyer

Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.

A Day in the Life Of... Serigne Lo
09 Feb 2018

A Day in the Life Of... Serigne Lo

A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia

Jay inspires others to help end melanoma and so can you
07 Feb 2018

Jay inspires others to help end melanoma and so can you

Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.

A dilemma no mother-to-be should face
31 Jan 2018

A dilemma no mother-to-be should face

Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment

Join little Madi and Bettina in the fight against melanoma
25 Jan 2018

Join little Madi and Bettina in the fight against melanoma

Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.